Adicet Bio, Inc. cotiza a 5.11 USD y tiene una capitalización bursátil de $48M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that tar…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.99 | $-1.88 | $-2.94 |
| Estimado | $-1.58 | $-1.64 | $-3.08 | $-2.99 |
| Sorpresa | — | -21.3% | +39.0% | +1.7% |
| Métrica | ACET | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -73.4% | -40.4% | -33.0% |
| ROA | -60.7% | -32.0% | -28.7% |
| Current Ratio | 7.47 | 2.84 | +4.63 |
| Debt / Equity | — | 0.28 | — |